↓ Skip to main content

Contemporary assessment and pharmacotherapy of Tourette syndrome

Overview of attention for article published in Neurotherapeutics, September 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

patent
3 patents
wikipedia
12 Wikipedia pages

Citations

dimensions_citation
271 Dimensions

Readers on

mendeley
208 Mendeley
connotea
1 Connotea
Title
Contemporary assessment and pharmacotherapy of Tourette syndrome
Published in
Neurotherapeutics, September 2012
DOI 10.1016/j.nurx.2006.01.009
Pubmed ID
Authors

Lawrence Scahill, Gerald Erenberg, Cheston M. Berlin, Cathy Budman, Barbara J. Coffey, Joseph Jankovic, Louise Kiessling, Robert A. King, Roger Kurlan, Anthony Lang, Jonathan Mink, Tanya Murphy, Samual Zinner, John Walkup

Abstract

To develop a guide to clinical assessment and pharmacotherapy for children and adults with Tourette syndrome (TS), we reviewed published literature over the past 25 years to identify original articles and reviews on the assessment and pharmacological treatment of Tourette syndrome, attention-deficit/hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD). The literature search also included a survey of reviews published in book chapters. The assessment section was compiled from several reviews. Pharmacological treatments were classified into those with strong empirical support (as evidenced by two positive placebo-controlled studies for tics, OCD, or ADHD in TS samples); modest empirical support (one positive placebo-controlled study), or minimal support (open-label data only). We conclude that accurate diagnosis, including identification of comorbid conditions, is an essential step toward appropriate treatment for patients with TS. In many patients with TS, symptom management requires pharmacotherapy for tics or coexisting conditions. The evidence supporting efficacy and safety for medications used in patients with TS varies. But this evidence offers the best guide to clinical practice.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 208 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 3 1%
United States 2 <1%
Argentina 2 <1%
Brazil 1 <1%
Uruguay 1 <1%
Unknown 199 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 32 15%
Student > Ph. D. Student 23 11%
Student > Bachelor 21 10%
Student > Master 18 9%
Other 18 9%
Other 58 28%
Unknown 38 18%
Readers by discipline Count As %
Medicine and Dentistry 70 34%
Psychology 41 20%
Neuroscience 18 9%
Agricultural and Biological Sciences 11 5%
Nursing and Health Professions 7 3%
Other 12 6%
Unknown 49 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 December 2022.
All research outputs
#5,446,210
of 25,373,627 outputs
Outputs from Neurotherapeutics
#570
of 1,308 outputs
Outputs of similar age
#38,925
of 186,989 outputs
Outputs of similar age from Neurotherapeutics
#12
of 36 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,989 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.